Activity of five quinolones, three macrolides and telithromycin against 12 Haemophilus influenzae strains with different resistance phenotypes

Clinical Microbiology and Infection

Volumn 11, Issue 12, 2005, Pages 1040-1044

  Pankuch, G A ^a   Lin, G ^a   Appelbaum, P C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Haemophilus influenzae; Kill kinetics; Macrolides; Quinolones; Resistance; Telithromycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFIXIME; CEFPODOXIME; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; MUTANT PROTEIN; QUINOLONE; RIBOSOME PROTEIN; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CULTURE MEDIUM; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

BACTERIA (MICROORGANISMS); HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; STREPTOCOCCUS PNEUMONIAE;

EID: 28644441427     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01288.x     Document Type: Article

References (22)

1. Needham CA. Haemophilus influenzae antibiotic susceptibility. Clin Microbiol Rev 1988; 1: 218-227.
2. Zeckel ML, Jacobson KD, Guerra FJ, Therasse DG, Farlow D. Loracarbef (LY 163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Ther 1992; 14: 214-229.
3. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7: 589-596.
4. Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Appelbaum PC. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 USA surveillance study. Antimicrob Agents Chemother 1999; 43: 1901-1908.
5. Dagan R, Johnson CE, McLinn S et al. Bacteriological and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19: 95-104.
6. Dagan R, Leibovitz E, Fliss DM et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44: 43-50.
7. Nazir J, Urban C, Mariano N et al. Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology. Clin Infect Dis 2004; 38: 1564-1569.
8. Matic V, Bozdogan B, Jacobs MR, Ubukata K, Appelbaum PC. Contribution of β-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in β-lactamase-positive, amoxicillin-resistant Haemophilus influenzae. J Antimicrob Chemother 2003; 52: 1018-1021.
9. Dabernat H, Delmas C, Seguy M et al. Diversity of β-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob Agents Chemother 2002; 46: 2208-2218.
10. Davies TA, Kelly LM, Hoellman DB et al. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 2000; 44: 633-639.
11. Clark CL, Bozdogan B, Peric M, Dewasse B, Jacobs MR, Appelbaum PC. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. Antimicrob Agents Chemother 2002; 46: 2956-2962.
12. Peric M, Bozdogan B, Galderisi C, Krissinger D, Rager T, Appelbaum PC. Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S. J Antimicrob Chemother 2004; 54: 393-400.
13. Peric M, Bozdogan B, Jacobs MR, Appelbaum PC. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 2003; 47: 1017-1022.
14. Clark C, Kosowska K, Bozdogan B et al. In vitro selection of resistance in Haemophilus influenzae by 4 quinolones and 5 β-lactams. Diagn Microbiol Infect Dis 2004; 49: 31-36.
15. Pankuch GA, Hoellman DB, Lin G, Bajaksouzian S, Jacobs MR, Appelbaum PC. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay. Antimicrob Agents Chemother 1998; 42: 3032-3034.
16. Credito KL, Lin G, Pankuch GA, Bajaksouzian S, Jacobs MR, Appelbaum PC. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents. Antimicrob Agents Chemother 2001; 45: 67-72.
17. Kosowska K, Credito K, Pankuch GA et al. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. Antimicrob Agents Chemother 2004; 48: 4113-4119.
18. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th edn. Approved standard M7-A6. Wayne, PA: NCCLS, 2003.
19. Goldstein FW, Emiran ME, Coutrot A, Acar JF. Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae. J Antimicrob Chemother 1990; 25(suppl A): 25-28.
20. Maskell JP, Sefton AM, Williams JD. Comparative in-vitro activity of azithromycin and erythromycin against gram-positive cocci, Haemophilus influenzae and anaerobes. J Antimicrob Chemother 1990; 25(suppl A): 19-24.
21. Neu HC. The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother 1991; 27(suppl A): 1-17.
22. Appelbaum PC, Gillespie SH, Burley CH, Tillotson GS. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. Int J Antimicrob Agents 2004; 23: 533-546.